Janssen Biotech

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Janssen Biotech sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 4 completed later-stage tilt upper quartile by trial count

Janssen Biotech: 8 sponsored US clinical trials, none currently recruiting.

Janssen Biotech sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 4 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ulcerative Colitis, with 2 trials.

Upper-quartile sponsor footprint

Janssen Biotech sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT02808780
ACTIVE NOT RECRUITING

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

NCT00606346
TERMINATED Phase 3

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

NCT01962974
COMPLETED Phase 3

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

NCT01550744
COMPLETED

An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

NCT01555606
COMPLETED Phase 2

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

NCT01314118
TERMINATED Phase 3

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

NCT01190839
COMPLETED Phase 3

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

NCT01004432

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 4

Therapeutic Areas

Ulcerative Colitis 2
Arthritis, Rheumatoid 1
Prostatic Neoplasm 1
Indeterminate Colitis 1
Inflammatory Bowel Diseases 1
Crohn's Disease 1
Arthritis 1
Autoimmune Diseases 1
Prostate Cancer 1

How the Janssen Biotech archive is shaped

8 indexed studies, none listed as recruiting (0% open); 4 completed (50%).

Phase mix: 4 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Ulcerative Colitis (2 trials), 8 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Janssen Biotech: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Janssen Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Janssen BiotechAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Janssen Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Janssen Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Janssen Biotech page

8 registered trials is a research-attention snapshot, not an endorsement of Janssen Biotech or any single study.

  • None of Janssen Biotech's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Ulcerative Colitis is the condition Janssen Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ulcerative Colitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Janssen Biotech pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.